LA JOLLA, Calif., May 18, 2016 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, today announced that Paul Grint, M.D., President and Chief Executive
Officer of Regulus, will present a company overview at the 2016 UBS
Global Healthcare Conference on Wednesday, May 25, 2016 at 8:00 a.m. ET. The conference is being held
at the Grand Hyatt Hotel in New York,
NY.
The presentation will be webcast at the time of the presentation
and can be accessed on the Investor Relations page of the Company's
website at www.regulusrx.com. A replay of the webcast will be
archived on the Company's website following the presentation
date.
About Regulus
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical
company leading the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a well-balanced microRNA therapeutics pipeline complemented by a
maturing microMarkersSM biomarkers platform and a rich
intellectual property estate to retain its leadership in the
microRNA field. Regulus is developing RG-101, a
GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment
of chronic hepatitis C virus infection, and RG-012, an anti-miR
targeting microRNA-21 for the treatment of Alport syndrome, a
life-threatening kidney disease driven by genetic mutations with no
approved therapy. In addition, RG-125, a GalNAc-conjugated
anti-miR targeting microRNA-103/107 for the treatment of NASH in
patients with type 2 diabetes/pre-diabetes, has entered Phase I
clinical development through its strategic alliance with
AstraZeneca. Regulus is also advancing several programs toward
clinical development in renal, hepatic and central nervous systems
diseases, both independently and with our strategic alliance
partners, Sanofi and AstraZeneca. Regulus' commitment to innovation
has resulted in multiple peer-reviewed publications in notable
scientific journals and has resulted in the formation of strategic
alliances with AstraZeneca and Sanofi. Regulus maintains its
corporate headquarters in La
Jolla, CA. For more information, please visit
http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected ability
of Regulus to undertake certain activities and accomplish certain,
the projected timeline of clinical development activities, and
expectations regarding future therapeutic and commercial potential
of Regulus' business plans, technologies and intellectual property
related to microRNA therapeutics and biomarkers being discovered
and developed by Regulus. Because such statements are subject
to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such
drugs. These and other risks concerning Regulus' financial
position and programs are described in additional detail in Regulus
filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Regulus undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regulus-to-present-at-the-2016-ubs-global-healthcare-conference-300271062.html
SOURCE Regulus Therapeutics Inc.